查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808345

低溫運輸醫藥市場按產品類型、包裝類型、溫度範圍、設備、服務類型、應用和最終用戶分類－2025-2030 年全球預測

Cold-chain Pharma Market by Product Type, Packaging Type, Temperature Range, Equipment, Service Type, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年低溫運輸醫藥市場規模將達153.9億美元，到2025年將以9.11%的複合年成長率成長至167.8億美元，到2030年將達到259.8億美元。

主要市場統計數據
基準年2024年 153.9億美元
預計2025年 167.8億美元
預測年份 2030 259.8億美元
複合年成長率（%） 9.11%

簡要介紹快速發展的全球醫療保健生態系統中醫藥低溫運輸物流的複雜性和戰略重要性

低溫運輸醫藥生態系統是一個複雜的交叉領域，融合了科學、物流和法律規範，是現代藥物傳遞的基礎。生技藥品、細胞和基因療法以及新一代疫苗的進步，提高了產品在時間和距離上保持完整性所需的技術嚴謹性，同時也擴大了必須合作以維持合規溫度曲線的利益相關人員的數量。

隨著技術、監管環境和以患者為中心的分銷模式對營運產生影響，變革性變化正在改變低溫運輸醫藥格局

隨著技術、法規和客戶期望的融合，產業動態正在迅速變化，重新定義有效的低溫運輸營運。數位化和遙測技術已從試點階段發展成為必不可少的控制措施，持續溫度監控、預測分析和基於區塊鏈的可追溯性也日益滲透到整個倉儲和運輸環節，從而加快了異常處理速度，並提高了監管透明度。

評估近期美國關稅和 2025 年貿易政策變化如何影響供應鏈成本壓力和路線決策的改變

美國近期推出的關稅和貿易政策變化（預計到2025年）為低溫運輸醫藥網路帶來了新的成本和路線考量。關稅正在改變採購和跨境運輸的經濟性，影響企業的生產、倉儲和最終加工地點。事實上，企業已採取應對措施，包括多元化供應商基礎、重新調整入境路線決策，並更依賴區域化網路，以降低關稅波動帶來的風險，並維持對時間敏感的冷鏈運輸。

詳細細分，確定產品類型、包裝、溫度控制、設備、服務、應用和最終用戶如何推動營運設計

精細的細分視角可以明確操作的複雜性所在，以及哪些功能能夠最大程度地降低風險。不同產品類型之間存在顯著差異。生技藥品需要針對單株抗體、血漿衍生療法和重組蛋白的通訊協定，這與血液和血漿製品（例如凝血因子和免疫球蛋白）的處理和儲存需求不同。細胞和基因療法具有獨特的限制，同種異體和自體細胞和基因療法通常需要用於臨床試驗材料（包括套件和臨床實驗藥物）的低溫鍊和專用輔助器具。胰島素和肽激素的設計需要考慮GLP-1和胰島素變異體，而特殊藥物（包括生育藥物和專用注射）則需要客製化的處理和交付時間表。疫苗種類繁多，從大流行疫苗和新興疫苗到常規免疫接種、旅行疫苗和特殊疫苗。大流行疫苗引入了mRNA和病毒載體的子類別，這些子類別對低溫儲存提出了獨特的要求。

美洲、歐洲、中東和非洲以及亞太地區的動態和基礎設施差異是低溫運輸策略的差異化因素

美洲、歐洲、中東和非洲以及亞太地區的區域基礎設施、管理體制和商業慣例差異巨大，導致營運環境差異巨大，需要製定量身定做的策略。在美洲，成熟的溫控倉庫、強大的航空貨運網路以及不斷發展的最後一英里生態系統支持快速商業化，但地域遼闊和地區監管差異通常意味著，區域樞紐和合格的最後一英里合作夥伴是實現全國覆蓋的先決條件。

塑造低溫運輸醫藥生態系統的競爭與協作企業行為，包括合作夥伴關係、專業化和差異化服務

我們看到，低溫運輸醫藥領域的企業正將專業化、夥伴關係和垂直整合結合，以追求競爭優勢。一些供應商專注於深度科技領域，例如超低溫物流、超低溫儲存或以臨床試驗為中心的服務，投資於獨特的處理通訊協定、專業的設備團隊和嚴格的資格認證程序，以在產品安全性和可靠性方面脫穎而出。其他參與者則強調服務廣度，提供集存儲、運輸、合規服務和數位視覺性於一體的端到端解決方案，從而簡化製造商和醫療保健提供者的供應商管理。

為高階主管提供切實可行的建議，透​​過投資、夥伴關係、合規和人才策略確保低溫運輸業務的未來發展

主管必須採取多管齊下的策略，確保低溫運輸營運面向未來，並在日益嚴苛的環境中獲取價值。首先，優先投資於可視性和分析技術，提供跨運輸和倉儲的即時遙測數據，從而實現主動異常管理和增強的審核追蹤。此外，還要透過流程控制、嚴格的資格確認通訊協定和定期審核來補充技術投資，確保數據得到經過檢驗的程序支援。

透明的調查方法，詳細說明低溫運輸評估的資料來源、檢驗程序、相關人員訪談和分析框架

調查方法結合了主要和次要證據流，建構了嚴謹透明的分析基礎。主要輸入包括對製造商、物流供應商和臨床試驗機構的供應鏈、品質和監管負責人進行結構化訪談，並輔以現場操作考察和流程演練，檢驗設施、包裝和溫控實踐。這些訪談重點關注通道檢驗經驗、最後一哩例外情況和設備資格確認了解實際的限制因素和緩解措施。

總結彈性合規的低溫運輸醫藥運輸的戰略意義、持續風險和現實前進道路

最後，低溫運輸醫藥產業正處於曲折點，產品創新、監管嚴謹性和地緣政治動態共同作用，提升了卓越營運的標準。積極協調遙測、高效包裝和區域網路靈活性投資的組織可以降低風險，並加快關鍵治療方法的可及性。同時，不斷變化的貿易政策和日益複雜的產品系列需要動態採購、完善的資格確認實踐和更強力的合約保護，以保持連續性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 整合區塊鏈追蹤平台，實現端到端低溫運輸可視性和合規性
  • 引入支援物聯網的智慧包裝解決方案，即時監控關鍵溫度偏差
  • 擴大超低溫儲存基礎設施，支持 mRNA 疫苗的全球分發
  • 將環保、可生物分解的隔熱材料引入低溫運輸運輸包裝
  • 生物製藥公司與專業第三方物流公司建立策略夥伴關係，實現最後一哩溫控配送
  • 監管協調努力旨在簡化跨境物流並減少合規延誤
  • 在自體細胞和基因治療中，從血液分離到輸注，透過冷凍保存快速識別和儲存個體
  • 實施人工智慧車道風險評分和預測性 ETD/ETA 規劃，主動避開容易延誤和偏差的路線
  • 機場和航空公司對 CEIV Pharma 設施和冷藏乾燥機的投資確保了藥品運輸的完整性
  • 使用數位雙胞胎和穩定性模型來設計強大的低溫運輸流程並主動管理累積熱暴露

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章低溫運輸藥品市場（依產品類型）

  • 生物製藥
    • 單株抗體
    • 血漿衍生療法
    • 重組蛋白和酶
  • 血液/血漿製品
    • 凝血因子
    • 免疫球蛋白
  • 細胞和基因治療
    • 同種異體細胞治療
    • 自體細胞治療
    • 基因治療
  • 臨床試驗材料
    • 配件和套件
    • 臨床實驗藥物
  • 胰島素和荷爾蒙
    • GLP-1和其他肽激素
    • 胰島素
  • 特種製藥
    • 不孕不育治療及生殖醫學
    • 特殊注射
  • 疫苗
    • 流行病和新興疫苗
      • mRNA疫苗
      • 病毒載體疫苗
    • 常規疫苗接種
    • 旅行和特殊疫苗

第9章低溫運輸藥品市場（依包裝類型）

  • 活性包裝
  • 被動封裝

第 10 章低溫運輸藥品市場（依溫度範圍）

  • 極低溫（-150度C以下）
    • 低溫包裝
    • 乾散貨運輸
    • LN2蒸氣儲存
  • 冷凍（-20至-40°C）
    • 包裹
    • 貯存
    • 運輸
  • 冷藏（2-8°C）
    • 包裹
    • 貯存
    • 運輸
  • 超低溫（-60至-86°C）
    • 包裹
    • 貯存
    • 運輸

第11章低溫運輸藥品市場（按設備）

  • 倉儲設備
    • 冷藏室和倉庫
    • 低溫冷凍庫和液態氮冷卻罐
    • 冷凍庫（-20度C級）
    • 藥品冷藏箱（2-8度C）
    • 超低溫冰箱（-80度C）
  • 運輸設備
    • 空運貨櫃（ULD）
    • 最後一英里可攜式冷卻器
    • 冷藏海運貨櫃
    • 冷藏卡車和貨車

第12章低溫運輸醫藥市場（依服務類型）

  • 臨床試驗物流
    • 輔助管理
    • 直接患者服務
    • 現場供應和退貨
  • 合規性和品質
    • 審核和GDP培訓
    • 車道檢驗和風險評估
    • 資質（IQ/OQ/PQ）
  • 儲存/倉儲
    • 低溫儲存
    • 長期 GMP 儲存
  • 運輸
    • 首英里接送
    • 最後一哩配送
    • 遠距
    • 逆向物流和退貨

第13章低溫運輸藥品市場（按應用）

  • 臨床試驗
  • 商業分銷
  • 直接送達患者/送貨上門
  • 人道援助和非政府組織供應
  • 專業藥房履約
  • 疫苗宣傳活動

第14章低溫運輸藥品市場（依最終用戶）

  • 血庫和血漿中心
  • 臨床試驗設施和倉庫
  • CMO 和 CDMO
  • CRO
  • 醫院和診所
  • 製藥和生物技術製造商
    • 新興生物技術
    • 大型製藥公司
  • 零售和專業藥局
  • 疫苗接種中心和公共衛生機構

15.美洲低溫運輸醫藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 歐洲、中東和非洲低溫運輸藥品市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

17. 亞太低溫運輸藥品市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第18章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • DHL International GmbH
    • FedEx Corporation
    • Americold Realty Trust, Inc.
    • AmerisourceBergen Corporation
    • CH Robinson Worldwide, Inc.
    • Catalent, Inc.
    • Clinigen Group PLC
    • Conestoga Cold Storage Ltd.
    • Continental AG
    • CWT Ltd.
    • DB Schenker
    • DSV A/S
    • Emergent Cold LatAm Management LLC
    • HCL Technologies Limited
    • Helapet ltd.
    • Interstate Cold Storage, Inc.
    • JWD InfoLogistics Public Co. Ltd.
    • Keppel Telecommunications & Transportation Ltd,
    • Kerry Logistics Network Limited by SF Holding Co., Ltd.
    • Kuehne+Nagel Management AG
    • Lineage, Inc.
    • Maersk A/S
    • NewCold Cooperatief UA
    • OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
    • SCG Logistics Management Co Ltd.
    • Tiong Nam Logistics Holdings Berhad
    • United Parcel Service, Inc.
    • Ych Group
    • Yusen Logistics Group
    • BioCold Technologies SAS
    • FreezPak Logistics

第19章 研究人工智慧

第20章 研究統計

第21章 研究聯絡人

第22章 研究報導

第23章 附錄

Product Code: MRR-7E6E70985BD9

The Cold-chain Pharma Market was valued at USD 15.39 billion in 2024 and is projected to grow to USD 16.78 billion in 2025, with a CAGR of 9.11%, reaching USD 25.98 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 15.39 billion
Estimated Year [2025] USD 16.78 billion
Forecast Year [2030] USD 25.98 billion
CAGR (%) 9.11%

A concise introduction to the complexity and strategic importance of cold-chain logistics for pharmaceuticals in a rapidly evolving global healthcare ecosystem

The cold-chain pharmaceutical ecosystem is a complex intersection of science, logistics and regulatory oversight that underpins modern therapeutics delivery. Advances in biologics, cell and gene therapies, and next-generation vaccines have increased the technical stringency required to preserve product integrity across time and distance, while expanding the number of stakeholders who must coordinate to maintain compliant temperature profiles.

Against this backdrop, supply chain leaders face pressures from rising demand for direct-to-patient fulfillment, heightened regulatory scrutiny, and the need to balance speed with reliability. Operational decisions now extend from packaging selection to route design and last-mile execution, each with implications for clinical outcomes and commercial viability. Moreover, the industry must integrate new equipment classes, from ultra-low freezers to cryogenic storage and purpose-built transport assets, while ensuring qualification and validation across complex multimodal flows.

This introduction frames the subsequent analysis by highlighting the interplay between product complexity, temperature control regimes, and service modalities. It sets the stage for an evidence-driven examination of transformative forces influencing capital allocation, partnership strategies, and risk management across pharmaceutical cold chains.

Transformative shifts reshaping the cold-chain pharma landscape driven by technology, regulatory change, and patient-centric distribution models impacting operations

Industry dynamics are shifting at pace as technology, regulations and customer expectations converge to redefine what constitutes an effective cold-chain operation. Digitization and telemetry have moved from experimental pilots to essential controls; continuous temperature monitoring, predictive analytics and blockchain-based traceability are increasingly embedded across storage and transport, enabling faster exception handling and improved regulatory transparency.

Concurrently, regulatory frameworks are evolving to reflect product innovation and higher patient-safety requisites. Good Distribution Practice enforcement and lane validation expectations have expanded, prompting firms to strengthen qualification protocols and invest in independent audits and training. At the same time, the rise of patient-centric distribution models such as direct-to-patient services is forcing a rethink of packaging design, last-mile solutions and temperature resiliency to preserve both efficacy and patient experience.

Operationally, climate resilience and sustainability are reshaping procurement and equipment lifecycles; companies are evaluating energy-efficient ULT freezers, low-emission transport options and circular packaging strategies. Taken together, these transformative shifts demand integrated strategies that align technical capabilities, regulatory compliance and commercial imperatives to maintain product integrity and ensure timely access to critical medicines.

Assessing how recent US tariff measures and trade policy shifts through 2025 are aggregating supply chain cost pressure and altering routing decisions

Recent tariff actions and trade policy changes originating from the United States through 2025 have introduced new cost and routing considerations for cold-chain pharmaceutical networks. Tariff measures alter the economics of sourcing and cross-border movement, influencing where firms choose to locate manufacturing, storage and finishing activities. In practice, organizations have responded by diversifying supplier bases, recalibrating inbound lane decisions and increasing reliance on regionalized networks to reduce exposure to tariff volatility and preserve time-sensitive cold flows.

These trade shifts also interact with modal selection and inventory strategies. Where tariffs elevate landed costs, companies may favor higher-capacity, less frequent shipments to dilute fixed expenses, or alternatively move to nearshoring and regional manufacturing to minimize cross-border touchpoints. Such changes have downstream implications for packaging and equipment choices, particularly when different temperature ranges require specialized containers or cryogenic handling that complicates rerouting.

Moreover, tariff-related uncertainty places a premium on contractual agility and trade compliance capabilities. Organizations that invest in robust tariff classification, free trade agreement utilization and dynamic contract terms are better positioned to mitigate sudden policy moves. In addition, scenario planning and lane-level risk assessments have become standard tools for supply chain leaders seeking to preserve product integrity while optimizing cost and service under shifting trade conditions.

Deep segmentation clarity revealing how product types, packaging, temperature control, equipment, services, applications, and end users dictate operational design

A granular segmentation lens clarifies where operational complexity is concentrated and which capabilities deliver the greatest risk mitigation. Product-type distinctions matter: biologics demand protocols for monoclonal antibodies, plasma-derived therapeutics and recombinant proteins that differ from the handling and storage needs of blood and plasma products such as coagulation factors and immunoglobulins. Cell and gene therapies present their own constraints, with allogeneic and autologous cell therapies and gene therapies often requiring cryogenic chains or specialized ancillaries used in clinical trial materials, including kits and investigational medicinal products. Insulins and peptide hormones bring design considerations for GLP-1 and insulin variants, while specialty pharmaceuticals including fertility medicines and specialty injectables impose bespoke handling and delivery timelines. Vaccines span pandemic and emerging vaccines, routine immunization and travel or specialty vaccines, with pandemic vaccines introducing mRNA and viral vector subcategories that drive unique cold requirements.

Packaging choices influence reliability and flexibility across those product groups. Active packaging solutions provide powered temperature control for highly sensitive payloads, whereas passive packaging affords simpler, proven containment for many refrigerated and frozen flows. Temperature-range segmentation demands distinct options from cryogenic solutions at or below -150 °C with cryo packaging and dry shippers, to frozen and ultra-low classes and the ubiquitous refrigerated 2-8 °C band where packaging, storage and transportation modalities must be matched to product stability profiles.

Equipment selection reinforces these distinctions. Storage equipment spans from cold rooms and GMP warehouses to cryogenic freezers, LN2 tanks, pharmaceutical refrigerators and ultra-low freezers, while transport fleets encompass air cargo containers, last-mile portable coolers, ocean reefer containers and reefer trucks. Service types overlay these hardware choices: clinical trial logistics that include ancillary management and direct-to-patient services; compliance and quality offerings such as audits, GDP training and lane validation; storage and warehousing solutions that include cryogenic and long-term GMP storage; and transportation services covering first-mile, line-haul and last-mile delivery plus reverse logistics and returns. Application contexts shape operational priorities, whether supporting clinical trials, commercial distribution, home delivery, humanitarian supply, specialty pharmacy fulfilment or vaccination campaigns.

End-user needs ultimately drive configuration. Blood banks, clinical trial sites and depots, CMOs, CDMOs and CROs require different SLA and qualification intensity compared with hospitals, clinics, retail specialty pharmacies and public health vaccination centers. Pharma and biotech manufacturers, from emerging biotech to large pharmaceutical companies, often act as the integrators of these requirements, defining service levels, validation expectations and capital investment criteria. Understanding how each segment interacts with packaging, temperature regimes, equipment and service models is essential to designing resilient cold-chain solutions that are fit for purpose and scalable across therapeutic categories.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated cold-chain strategies

Regional infrastructure, regulatory regimes and commercial practices create materially different operating environments across the Americas, Europe Middle East & Africa, and Asia-Pacific, requiring tailored strategies for each geography. In the Americas, maturity in temperature-controlled warehousing, a strong air cargo network and a growing last-mile ecosystem support rapid commercialization, but vast distances and localized regulatory nuances mean that regional hubs and qualified last-mile partners are often prerequisites for nationwide coverage.

In Europe, Middle East & Africa, dense cross-border trade within the European Union coexists with highly variable capabilities across other markets, necessitating robust lane validation and comprehensive compliance programs to harmonize operations. The regulatory emphasis on GDP and lane qualification in many EMEA jurisdictions places a premium on audit-ready documentation and validated cold-chain partners, while infrastructure gaps in parts of the region can drive investment in contingency planning and purpose-built storage nodes.

Asia-Pacific delivers a heterogeneous mix of advanced hubs and emerging markets. Rapid vaccine rollouts and biotechnology innovation have accelerated investments in ultra-low and cryogenic storage in major markets, whereas emerging economies often require creative last-mile and packaging adaptations to contend with climatic variation and limited cold-room capacity. Across all regions, cross-border trade dynamics and trade policy changes influence network design, so a regionalized approach that blends centralized centers of excellence with local operational capacity reduces risk and improves responsiveness to demand shocks.

Competitive and collaborative company behaviors shaping the cold-chain pharmaceutical ecosystem including partnerships, specialization, and service differentiation

Company behaviors in the cold-chain pharmaceutical space reveal a mix of specialization, partnership and vertical integration as firms pursue competitive advantage. Some providers focus on deep technical niches-such as cryogenic logistics, ultra-low temperature storage or clinical-trial-centric services-investing in proprietary handling protocols, specialized equipment fleets and rigorous qualification programs to differentiate on product safety and reliability. Other players emphasize breadth, offering end-to-end solutions that combine storage, transport, compliance services and digital visibility, thereby simplifying supplier management for manufacturers and healthcare providers.

Strategic partnerships and alliances are increasingly common, enabling companies to marry local last-mile expertise with global air cargo and warehousing capabilities. Collaboration with technology vendors provides telemetry, predictive maintenance and analytic tooling that translate operational data into fewer temperature excursions and faster root-cause analysis. Meanwhile, a number of organizations pursue selective vertical integration-bringing storage or packaging capabilities in-house-to safeguard control over critical flows during product launches or pandemic-scale campaigns.

From the buyer perspective, selection criteria are shifting beyond price to emphasize demonstrable GDP compliance, lane validation experience, failure-mode analysis, and the ability to scale rapidly during demand surges. Companies that invest in cross-functional teams combining regulatory, quality and operations expertise are better positioned to win long-term engagements with manufacturers and health systems.

Actionable recommendations for senior executives to future-proof cold-chain operations through investment, partnerships, compliance, and workforce strategy

Leaders must adopt a multi-dimensional strategy to future-proof cold-chain operations and capture value in an increasingly demanding environment. First, prioritize investments in visibility and analytics that provide real-time telemetry across transport and storage, enabling proactive exception management and stronger audit trails. Complement technology investments with process controls, robust qualification protocols and recurring audits to ensure data is supported by validated procedures.

Second, pursue a regionalized network design that balances centralized centers of excellence for high-complexity products with localized last-mile capabilities to guarantee service continuity. Where trade policy or tariffs create volatility, nearshoring and diversified supplier strategies reduce exposure and shorten lead times. Third, update packaging and equipment policies to reflect evolving product mixes; specify active or passive packaging solutions aligned to temperature ranges from cryogenic to refrigerated 2-8 °C, and standardize equipment qualification across warehouses and transport assets to reduce variability.

Fourth, strengthen commercial contracts and procurement practices to include flexible terms for surge capacity, clear responsibilities for exception handling and shared obligations for qualification. Fifth, invest in workforce capability through targeted GDP training and cross-functional simulations that include quality, operations and regulatory teams, ensuring readiness for complex launches and emergency responses. Finally, embed sustainability objectives into CAPEX and lifecycle decisions, selecting energy-efficient equipment and circular packaging models where they also reinforce reliability and compliance.

Transparent research methodology detailing data sources, validation steps, stakeholder interviews, and analytical frameworks applied to cold-chain assessment

The research methodology combined primary and secondary evidence streams to create a rigorous, transparent foundation for analysis. Primary inputs included structured interviews with supply chain, quality and regulatory leaders across manufacturers, logistics providers and clinical trial organizations, supported by operational site visits and process walkthroughs that validated equipment, packaging and temperature-control practices. These interviews emphasized lane validation experiences, last-mile exceptions, and equipment qualification practices to capture real-world constraints and mitigation approaches.

Secondary sources comprised regulatory guidelines, technical standards, trade policy documents and equipment specifications that were synthesized to ensure alignment with current compliance expectations. A multi-step validation process reconciled interview findings with documentary evidence, and key assertions were cross-checked against multiple independent sources where available. Analytical frameworks incorporated failure-mode effects analysis for high-risk lanes, scenario-based planning for tariff and trade disruptions, and capability-matrix mapping to link product types to packaging and equipment requirements.

Throughout the process, care was taken to anonymize sensitive operational details and to prioritize reproducibility: assumptions and inclusion criteria are documented, and methodological limitations are acknowledged, including variability across jurisdictions and the rapid evolution of technology and regulatory practice.

Concluding synthesis of strategic implications, lingering risks, and pragmatic pathways for resilient and compliant cold-chain pharma delivery

In closing, the cold-chain pharmaceutical landscape is at an inflection point where product innovation, regulatory rigor and geopolitical dynamics collectively raise the bar for operational excellence. Organizations that proactively align investments in telemetry, validated packaging, and regional network flexibility will reduce risk and accelerate access to critical therapies. At the same time, trade policy volatility and increasing complexity in product portfolios require dynamic procurement, robust qualification practices and stronger contractual protections to maintain continuity.

Lingering risks include infrastructure variability across regions, talent shortages for specialized handling, and the potential for tariff or trade disruptions to disrupt established lanes. However, pragmatic pathways exist: prioritize auditable processes, cultivate partnerships that combine global reach with local execution, and invest in workforce and technology capabilities that translate data into decisive action. Executives who integrate these dimensions into a coherent strategic roadmap will not only protect product integrity but also create operational agility that supports rapid launches and resilient commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of blockchain-enabled tracking platforms for end-to-end cold-chain visibility and compliance
  • 5.2. Adoption of IoT-enabled smart packaging solutions to monitor critical temperature deviations in real time
  • 5.3. Scaling infrastructure for ultra-low temperature storage to support mRNA vaccine distribution at global scale
  • 5.4. Implementation of eco-friendly biodegradable thermal insulation materials in cold-chain transport packaging
  • 5.5. Strategic partnerships between biopharma companies and specialized 3PLs for last-mile temperature-controlled deliveries
  • 5.6. Regulatory harmonization efforts to streamline cross-border cold-chain pharma logistics and reduce compliance delays
  • 5.7. Acceleration of cryogenic chain-of-identity and custody for autologous cell and gene therapies from apheresis to infusion
  • 5.8. Deployment of AI-driven lane risk scoring and predictive ETD/ETA planning to preempt delays and excursion-prone routings
  • 5.9. Airport and airline investments in CEIV Pharma facilities and cool dollies to protect ramp integrity for pharma consignments
  • 5.10. Use of digital twins and stability modeling to design robust cold-chain flows and proactively manage cumulative thermal exposure

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cold-chain Pharma Market, by Product Type

  • 8.1. Introduction
  • 8.2. Biologics
    • 8.2.1. Monoclonal Antibodies
    • 8.2.2. Plasma-Derived Therapeutics
    • 8.2.3. Recombinant Proteins & Enzymes
  • 8.3. Blood & Plasma Products
    • 8.3.1. Coagulation Factors
    • 8.3.2. Immunoglobulins
  • 8.4. Cell & Gene Therapies
    • 8.4.1. Allogeneic Cell Therapies
    • 8.4.2. Autologous Cell Therapies
    • 8.4.3. Gene Therapies
  • 8.5. Clinical Trial Materials
    • 8.5.1. Ancillaries & Kits
    • 8.5.2. Investigational Medicinal Products
  • 8.6. Insulins & Hormones
    • 8.6.1. GLP-1 & Other Peptide Hormones
    • 8.6.2. Insulin
  • 8.7. Specialty Pharmaceuticals
    • 8.7.1. Fertility & Reproductive Medicines
    • 8.7.2. Specialty Injectables
  • 8.8. Vaccines
    • 8.8.1. Pandemic & Emerging Vaccines
      • 8.8.1.1. mRNA Vaccines
      • 8.8.1.2. Viral Vector Vaccines
    • 8.8.2. Routine Immunization Vaccines
    • 8.8.3. Travel & Specialty Vaccines

9. Cold-chain Pharma Market, by Packaging Type

  • 9.1. Introduction
  • 9.2. Active Packaging
  • 9.3. Passive Packaging

10. Cold-chain Pharma Market, by Temperature Range

  • 10.1. Introduction
  • 10.2. Cryogenic (<= -150 °C)
    • 10.2.1. Cryo Packaging
    • 10.2.2. Dry Shipper Transport
    • 10.2.3. LN2 Vapor Storage
  • 10.3. Frozen (-20 To -40 °C)
    • 10.3.1. Packaging
    • 10.3.2. Storage
    • 10.3.3. Transportation
  • 10.4. Refrigerated (2-8 °C)
    • 10.4.1. Packaging
    • 10.4.2. Storage
    • 10.4.3. Transportation
  • 10.5. Ultra-Low (-60 To -86 °C)
    • 10.5.1. Packaging
    • 10.5.2. Storage
    • 10.5.3. Transportation

11. Cold-chain Pharma Market, by Equipment

  • 11.1. Introduction
  • 11.2. Storage Equipment
    • 11.2.1. Cold Rooms & Warehouses
    • 11.2.2. Cryogenic Freezers & LN2 Tanks
    • 11.2.3. Freezers (-20 °C Class)
    • 11.2.4. Pharmaceutical Refrigerators (2-8 °C)
    • 11.2.5. ULT Freezers (-80 °C Class)
  • 11.3. Transport Equipment
    • 11.3.1. Air Cargo Containers (ULDs)
    • 11.3.2. Last-Mile Portable Coolers
    • 11.3.3. Ocean Reefer Containers
    • 11.3.4. Reefer Trucks & Vans

12. Cold-chain Pharma Market, by Service Type

  • 12.1. Introduction
  • 12.2. Clinical Trial Logistics
    • 12.2.1. Ancillary Management
    • 12.2.2. Direct-To-Patient Services
    • 12.2.3. Site Supply And Returns
  • 12.3. Compliance & Quality
    • 12.3.1. Audits & GDP Training
    • 12.3.2. Lane Validation & Risk Assessment
    • 12.3.3. Qualification (IQ/OQ/PQ)
  • 12.4. Storage & Warehousing
    • 12.4.1. Cryogenic Storage
    • 12.4.2. Long-Term GMP Storage
  • 12.5. Transportation
    • 12.5.1. First-Mile Pickup
    • 12.5.2. Last-Mile Delivery
    • 12.5.3. Line-Haul Transport
    • 12.5.4. Reverse Logistics & Returns

13. Cold-chain Pharma Market, by Application

  • 13.1. Introduction
  • 13.2. Clinical Trials
  • 13.3. Commercial Distribution
  • 13.4. Direct-To-Patient/Home Delivery
  • 13.5. Humanitarian & NGO Supply
  • 13.6. Specialty Pharmacy Fulfillment
  • 13.7. Vaccination Campaigns

14. Cold-chain Pharma Market, by End User

  • 14.1. Introduction
  • 14.2. Blood Banks & Plasma Centers
  • 14.3. Clinical Trial Sites & Depots
  • 14.4. CMOs & CDMOs
  • 14.5. CROs
  • 14.6. Hospitals & Clinics
  • 14.7. Pharma & Biotech Manufacturers
    • 14.7.1. Emerging Biotech
    • 14.7.2. Large Pharmaceutical Companies
  • 14.8. Retail & Specialty Pharmacies
  • 14.9. Vaccination Centers & Public Health Agencies

15. Americas Cold-chain Pharma Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Cold-chain Pharma Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Cold-chain Pharma Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. DHL International GmbH
    • 18.3.2. FedEx Corporation
    • 18.3.3. Americold Realty Trust, Inc.
    • 18.3.4. AmerisourceBergen Corporation
    • 18.3.5. C.H. Robinson Worldwide, Inc.
    • 18.3.6. Catalent, Inc.
    • 18.3.7. Clinigen Group PLC
    • 18.3.8. Conestoga Cold Storage Ltd.
    • 18.3.9. Continental AG
    • 18.3.10. CWT Ltd.
    • 18.3.11. DB Schenker
    • 18.3.12. DSV A/S
    • 18.3.13. Emergent Cold LatAm Management LLC
    • 18.3.14. HCL Technologies Limited
    • 18.3.15. Helapet ltd.
    • 18.3.16. Interstate Cold Storage, Inc.
    • 18.3.17. JWD InfoLogistics Public Co. Ltd.
    • 18.3.18. Keppel Telecommunications & Transportation Ltd,
    • 18.3.19. Kerry Logistics Network Limited by SF Holding Co., Ltd.
    • 18.3.20. Kuehne + Nagel Management AG
    • 18.3.21. Lineage, Inc.
    • 18.3.22. Maersk A/S
    • 18.3.23. NewCold Cooperatief UA
    • 18.3.24. OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
    • 18.3.25. SCG Logistics Management Co Ltd.
    • 18.3.26. Tiong Nam Logistics Holdings Berhad
    • 18.3.27. United Parcel Service, Inc.
    • 18.3.28. Ych Group
    • 18.3.29. Yusen Logistics Group
    • 18.3.30. BioCold Technologies S.A.S
    • 18.3.31. FreezPak Logistics

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. COLD-CHAIN PHARMA MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. COLD-CHAIN PHARMA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COLD-CHAIN PHARMA MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. COLD-CHAIN PHARMA MARKET: RESEARCHAI
  • FIGURE 30. COLD-CHAIN PHARMA MARKET: RESEARCHSTATISTICS
  • FIGURE 31. COLD-CHAIN PHARMA MARKET: RESEARCHCONTACTS
  • FIGURE 32. COLD-CHAIN PHARMA MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. COLD-CHAIN PHARMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 239. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 241. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 243. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 245. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 247. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 249. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 251. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 253. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 257. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 259. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 261. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2025-2030 (USD MILLION)
  • TABLE 263. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2025-2030 (USD MILLION)
  • TABLE 265. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 267. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 269. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 271. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2025-2030 (USD MILLION)
  • TABLE 275. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2025-2030 (USD MILLION)
  • TABLE 277. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2025-2030 (USD MILLION)
  • TABLE 279. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2025-2030 (USD MILLION)
  • TABLE 281. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 285. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2025-2030 (USD MILLION)
  • TABLE 287. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 311. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 313. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 315. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES COLD-